Knight Therapeutics (TSE:GUD) Sets New 12-Month High – Time to Buy?

Knight Therapeutics Inc. (TSE:GUD)’s share price hit a new 52-week high during trading on Wednesday . The stock traded as high as C$8.87 and last traded at C$8.62, with a volume of 146776 shares changing hands. The stock had previously closed at C$8.66.

Analyst Ratings Changes

Separately, Canaccord Genuity Group set a C$9.50 price objective on Knight Therapeutics and gave the company a “buy” rating in a research report on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of C$9.50.

Knight Therapeutics Stock Up 1.8%

The company has a debt-to-equity ratio of 8.86, a quick ratio of 1.79 and a current ratio of 2.32. The stock has a market capitalization of C$848.90 million, a PE ratio of 144.00, a PEG ratio of -1,013.50 and a beta of -0.21. The business has a 50 day moving average of C$7.26 and a two-hundred day moving average of C$6.46.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings data on Thursday, May 7th. The company reported C$0.13 earnings per share for the quarter. The firm had revenue of C$147.59 million during the quarter. Knight Therapeutics had a return on equity of 0.73% and a net margin of 1.10%. Analysts predict that Knight Therapeutics Inc. will post 0.1009486 EPS for the current year.

About Knight Therapeutics

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.